Arrowhead ResearchARWR
ARWR
About: Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular disease.
Employees: 609
0
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
2% more repeat investments, than reductions
Existing positions increased: 90 | Existing positions reduced: 88
8% less first-time investments, than exits
New positions opened: 34 | Existing positions closed: 37
1% less funds holding
Funds holding: 271 [Q2] → 268 (-3) [Q3]
3.11% less ownership
Funds ownership: 80.22% [Q2] → 77.1% (-3.11%) [Q3]
28% less capital invested
Capital invested by funds: $2.59B [Q2] → $1.85B (-$735M) [Q3]
60% less funds holding in top 10
Funds holding in top 10: 5 [Q2] → 2 (-3) [Q3]
61% less call options, than puts
Call options by funds: $3.3M | Put options by funds: $8.52M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$24
23%
upside
Avg. target
$46
136%
upside
High target
$80
310%
upside
6 analyst ratings
4 positive
67%
2 neutral
33%
0 negative
0%
HC Wainwright & Co. Patrick Trucchio 29% 1-year accuracy 46 / 158 met price target | 310%upside $80 | Buy Reiterated | 20 Dec 2024 |
Chardan Capital Keay Nakae 28% 1-year accuracy 20 / 72 met price target | 207%upside $60 | Buy Maintained | 12 Dec 2024 |
Bernstein William Pickering 0% 1-year accuracy 0 / 5 met price target | 23%upside $24 | Market Perform Maintained | 29 Nov 2024 |
Piper Sandler Edward Tenthoff 21% 1-year accuracy 9 / 43 met price target | 130%upside $45 | Overweight Maintained | 27 Nov 2024 |
Citigroup Shawn Egan 0 / 0 met price target | 33%upside $26 | Neutral Maintained | 27 Nov 2024 |
Financial journalist opinion
Based on 9 articles about ARWR published over the past 30 days
Neutral
Business Wire
3 days ago
Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the company's investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. Arrowhead also filed recently a request for regulatory clearance to initiate a clinical trial for its second obesity candidate, ARO-ALK7. Both ARO-INHBE and ARO-ALK7 are designed to intervene in a kn.
Neutral
Business Wire
1 week ago
Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 13, 2024, the Company's Board of Directors approved “inducement” grants to 20 new employees under Rule 5635(c)(4) of the NASDAQ Listing Rules. The grants entitle employees, in aggregate, to receive up to 44,350 restricted stock units. The grants are outside the Company's stockholder-approved equity incentive plans and v.
Neutral
Business Wire
2 weeks ago
Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company's investigational RNA interference (RNAi) therapeutic targeting complement factor B being developed as a potential treatment for complement mediated diseases. The data were presented today, December 11, 2024, at the 8th Complement-Based Drug Development Summit being held in Boston. “Dysregulated activation of the complement sy.
Neutral
Business Wire
3 weeks ago
Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-ALK7 for the Treatment of Obesity
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has filed a request for regulatory clearance to initiate a Phase 1/2a clinical trial of ARO-ALK7, the company's second investigational RNA interference (RNAi) therapeutic being developed as a potential treatment for obesity. ARO-ALK7 is the first RNAi-based therapy to directly target a gene expressed in adipose tissue and highlights Arrowhead's leadership in the delivery of siRNA to multipl.
Neutral
Business Wire
3 weeks ago
Arrowhead Pharmaceuticals to Participate in Upcoming December 2024 Conferences
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events: Piper Sandler 36th Annual Healthcare Conference – December 3-5, 2024 Type: Fireside Chat Presentation Date/Time: December 3, 2024, 1:30 p.m. EST 7th Annual Evercore ISI HealthCONx Conference – December 3-5, 2024 Type: Fireside Chat Presentation Date/Time: December 4, 2024, 2:10 p.m. EST The APA/JPS/CAP/IAP 2024 Joint Meeting – De.
Neutral
Seeking Alpha
4 weeks ago
Arrowhead Pharmaceuticals, Inc. (ARWR) Q4 2024 Earnings Call Transcript
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q4 2024 Earnings Conference Call November 26, 2024 4:30 PM ET Company Participants Vince Anzalone - VP, IR Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical Scientist Andy Davis - SVP & Head of Global Cardiometabolic Franchise James Hamilton - Chief Discovery & Translational Medicine Ken Myszkowski - CFO Conference Call Participants Jasmine Fels - UBS Luca Issi - RBC Capital Andrea Newkirk - Goldman Sachs Maury Raycroft - Jefferies Dina Ramadane - Bank of America Patrick Trucchio - H.C. Wainwright Edward Tenthoff - PSC Mayank Mamtani - B.
Neutral
Business Wire
4 weeks ago
Arrowhead Pharmaceuticals Reports 2024 Fiscal Year-End Results
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its 2024 fiscal year ended September 30, 2024. The Company is hosting a conference call today, November 26, 2024, at 4:30 p.m. ET to discuss the results. “Arrowhead is well positioned, both individually and with partners, to advance and ultimately commercialize important new medicines using our proprietary TRiM™ technology. We have the potential to impact the lives of millions.
Neutral
Investors Business Daily
4 weeks ago
Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta
Shares of Arrowhead Pharmaceuticals catapulted Tuesday after the company inked a broad licensing deal with Sarepta Therapeutics. The post Arrowhead Launches 25% On A Massive Licensing Deal With Sarepta appeared first on Investor's Business Daily.
Neutral
Business Wire
1 month ago
Sarepta Therapeutics Announces Global Licensing and Collaboration Agreement with Arrowhead Pharmaceuticals for Multiple Clinical and Preclinical siRNA Programs
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an exclusive global licensing and collaboration agreement with Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR). Sarepta will obtain exclusive global rights to multiple clinical, preclinical, and discovery-stage programs for rare, genetic diseases of the muscle, central nervous system (CNS), and the lungs. The agreement will add meaningfully to S.
Neutral
Business Wire
1 month ago
Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for investigational plozasiran for the treatment of familial chylomicronemia syndrome (FCS), a severe and rare genetic disease which currently has no FDA approved treatments. Arrowhead also intends to submit applications for approval of investigational plozasiran for the treatment of patients with FCS to a.
Charts implemented using Lightweight Charts™